Follow Us: social media social media social media        

Reminyl®(galantaminehydrobromide): New Warning: Serious skin reactions (Stevens Johnson Syndrome [SJS] and acute generalised exanthematous pustulosis [AGEP])

Date: 17 December 2014

Description: The NPCB would like to alert healthcare professionals that cases of serious skin reactions (Stevens Johnson Syndrome and acute generalized exanthematous pustulosis) have been reported with the use of Reminyl®. Patients must be counselled on the signs of serious skin reactions, and Reminyl® treatment should be discontinued at the first appearance of skin rash. For further details, please refer to the Direct Healthcare Professional Communication (DHPC) issued by Janssen, a division of Johnson & Johnson Sdn. Bhd., in agreement with NPCB.

Like Us on Facebook

qrcode